Once-Weekly Insulin Icodec Wins; Wegovy Heart Data Soon; AACE's T2D Algorithm Update

Compared with once-daily insulin glargine U100, once-weekly icodec performed similarly for glycemic control, but needed fewer basal insulin injections and a lower bolus insulin dose, and had no increase in hypoglycemic rates in type 2 diabetes patients, according to the phase IIIa ONWARDS 4 trial. (The Lancet)

In a real-world study of nearly half a million postmenopausal women, those who started on denosumab injection (Prolia) had a significantly lower relative risk for a bunch of different fracture types compared with those on oral alendronate, Amgen announced.

Highly anticipated major cardiovascular data with the popular weight-loss drug semaglutide (Wegovy) is expected as early as June. (Reuters)

And because of unprecedented demand for the drug, Novo Nordisk announced plans to limit availability of lower-dose starter formulations to safeguard continuity of care.

The American Association of Clinical Endocrinology (AACE) just released a new update to its comprehensive type 2 diabetes management algorithm at its annual meeting last week. Catch up on coverage from the meeting here.

People who stuck to the American Heart Association's Life's Essential 8 recommendations saw clinically significant weight loss. (Journal of the American Heart Association)

Some state regulators are raising the alarm on compounding pharmacists making copycat versions of Ozempic and Wegovy using a form of semaglutide not approved by the FDA. (NBC News)

Sons of women with polycystic ovary syndrome (PCOS) were more likely to have obesity and dyslipidemia, a case-control study showed. (Cell Reports Medicine)

Led by New York and California, other states are introducing laws requiring manufacturers of menstrual products to disclose all ingredients, potentially revealing carcinogens, reproductive toxicants, endocrine disruptors, and allergens. (KFF Health News)

Comment